Page 24 - Read Online

Page 6 of 7 Komiya et al. J Cancer Metastasis Treat 2020;6:4 I http://dx.doi.org/10.20517/2394-4722.2019.41

Authors’ contributions
Substantial contributions to conception and design of the study and performed data analysis and
interpretation: Komiya T
Data acquisition, as well as provided administrative, technical, and material support: Komiya T
Manuscript writing: Komiya T, Chaaya G, Deshotels L, Powell E, Guddati AK

Availability of data and materials
List of clinical trials as primary data source can be found as supplemental information.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: cancer of any site.
Available from: https://seer.cancer.gov/statfacts/html/all.html [Last accessed on 19 Feb 2020]
2. Al-Baimani K, Jonker H, Zhang T, Goss GD, Laurie SA, et al. Are clinical trial eligibility criteria an accurate reflection of a real-world
population of advanced non-small-cell lung cancer patients? Curr Oncol 2018;25:e291-7.
3. American Society of Clinical Oncology. Two cancer research organizations submit recommendations to FDA aimed at reducing
barriers to clinical trial participation. Available from: https://www.asco.org/about-asco/press-center/news-releases/two-cancer-research-
organizations-submit-recommendations-fda [Last accessed on 19 Feb 2020]
4. Lin NU, Prowell T, Tan AR, Kozak M, Rosen O, et al. Modernizing clinical trial eligibility criteria: recommendations of the american
society of clinical oncology-friends of cancer research brain metastases working group. J Clin Oncol 2017;35:3760-73.
5. Uldrick TS, Ison G, Rudek MA, Noy A, Schwartz K, et al. Modernizing clinical trial eligibility criteria: recommendations of the american
society of clinical oncology-friends of cancer research HIV working group. J Clin Oncol 2017;35:3774-80.
6. Lichtman SM, Harvey RD, Damiette Smit MA, Rahman A, Thompson MA, et al. Modernizing clinical trial eligibility criteria:
recommendations of the american society of clinical oncology-friends of cancer research organ dysfunction, prior or concurrent
malignancy, and comorbidities working group. J Clin Oncol 2017;35:3753-9.
7. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of Phase III trials for patients with extensive-stage small-cell lung
cancer: perceptible progress. J Clin Oncol 1999;17:1794-801.
8. Chen TT, Chute JP, Feigal E, Johnson BE, Simon R. A model to select chemotherapy regimens for Phase III trials for extensive-stage
small-cell lung cancer. J Natl Cancer Inst 2000;92:1601-7.
9. Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, et al. Twenty-seven years of Phase III trials for patients with extensive disease small-cell
lung cancer: disappointing results. PLoS One 2009;4:e7835.
10. Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years?
Oncologist 2007;12:1096-104.
11. Small cell Lung Cancer. NCCN clinical practice guidelines in oncology. Version I.2019. Available from: https://www.nccn.org/
professionals/physician_gls/pdf/sclc.pdf [last accessed on 19 Feb 2020]
12. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung
cancer. N Engl J Med 2017;377:829-38.
13. Beaver JA, Ison G, Pazdur R. Reevaluating eligibility criteria - balancing patient protection and participation in oncology trials. N Engl J
Med 2017;376:1504-5.